GSK1070916 is a novel, azaindole derived, reversible and ATP-competitive inhibitor of the Aurora B/C kinases. GSK1070916 inhibits the proliferation of tumor cells and has antitumor effects in 10 human tumor xenograft models including breast, colon, lung, and two leukemia models. Nemucore Medical Innovations and Cancer Research UK are developing NMI 900 (previously GSK 1070916) for the intravenous treatment of cancer. The product was originally developed by GlaxoSmithKline. A phase I/II trial in patients with solid tumours has been completed in the UK. Phase II development in ovarian cancer is underway in the US.

N,N-dimethylglycine or dimethylglycine (DMG) is an amino acid derivative found in the cells of all plants and animals and can be obtained in the diet in small amounts from grains and meat. The human body produces DMG when metabolizing choline into glycine. DMG has been found acting at glycine binding site of the N-methyl-d-aspartate receptor (NMDAR). DMG has had wide acceptance as a nonfuel nutrient; presumably it enhances oxygen utilization by tissue and complexes free radicals. There were published studies, which have shown little to no difference between DMG treatment and placebo in autism spectrum disorders and the same no effect was observed in case of investigated DMG for epilepsy. This compound was also suggested to use to improve the athletic performance enhancer, but this usage was ineffective as well.

N,N-dimethylglycine or dimethylglycine (DMG) is an amino acid derivative found in the cells of all plants and animals and can be obtained in the diet in small amounts from grains and meat. The human body produces DMG when metabolizing choline into glycine. DMG has been found acting at glycine binding site of the N-methyl-d-aspartate receptor (NMDAR). DMG has had wide acceptance as a nonfuel nutrient; presumably it enhances oxygen utilization by tissue and complexes free radicals. There were published studies, which have shown little to no difference between DMG treatment and placebo in autism spectrum disorders and the same no effect was observed in case of investigated DMG for epilepsy. This compound was also suggested to use to improve the athletic performance enhancer, but this usage was ineffective as well.